Oncotarget

Meta-Analysis:

Glucose transporter1 as an independent prognostic marker for cancer: a metaanalysis

PDF  |  Full Text  |  How to cite

Zheng-Xiao Zhao1,2, Lin-Wei Lu1,2, Jian Qiu1,2, Qiu-Ping Li1,2, Fei Xu1,2, Bao-Jun Liu1,2, Jing-Cheng Dong1,2 and Wei-Yi Gong1,2

1Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China

2The Academy of Integrative Medicine of Fudan University, Shanghai 200032, P.R. China

Correspondence to:

Wei-Yi Gong, email: onlygwy119@163.com

Keywords: Glucose transporter-1, GLUT-1, cancer, prognosis, meta-analysis

Received: February 23, 2017     Accepted: June 18, 2017     Published: July 04, 2017

ABSTRACT

Objective: Glucose transporter-1 (GLUT-1) as the major glucose transporter present in human cells is found overexpressed in a proportion of human malignancies. This meta-analysis is attempted to assess the prognostic significance of GLUT-1 for survival in various cancers.

Materials and Methods: We conducted an electronic search using the databases PubMed, Embase and Web of Science, from inception to Oct 20th, 2016. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated.

Results: Fourty-one studies with a total of 4794 patients were included. High GLUT-1 expression was significantly associated with poorer prognosis [overall survival: HR = 1.833 (95% CI: 1.597–2.069, P < 0.0001); disease-free survival: HR = 1.838 (95% CI: 1.264–2.673, P < 0.0001); progression-free survival: HR = 2.451 (95% CI: 1.668–3.233, P < 0.0001); disease specific survival: HR = 1.96 (95% CI: 1.05–2.871, P < 0.0001)].

Conclusions: High GLUT-1 expression may be an independent prognostic marker to predict poor survival in various types of cancers. Further clinical trials with high quality need to be conducted to confirm our conclusion.